Discover
NVCT
Nuvectis Pharma, Inc.
19.52
2 x 14.46
2 x 23.87
bid
ask
+
1.13
6.14%
2 @ 04:00 PM
19.99 +0.47 (2.41%)
| Ytd | 158.54% | |
| 1y | 159.57% |
18.42
day range
20.20
5.55
52 week range
29.27
| Open | 18.61 | Prev Close | 18.39 | Low | 18.42 | High | 20.20 | Mkt Cap | 615.38M |
| Vol | 899.20K | Avg Vol | 217.34K | EPS | -1.31 | P/E | N/A | Forward P/E | -4.77 |
| Beta | 0.40 | Short Ratio | 5.30 | Inst. Own | 6.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 12.14 | 200-d Avg | 8.63 | 1yr Est | 22.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-05 | 2024-09 | -0.26 | -0.24 | 0.02 | 7.69% |
| 2024-08-06 | 2024-06 | -0.26 | N/A | N/A | N/A |
| 2024-08-06 | 2024-06 | -0.26 | -0.26 | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.4 | -0.25 | 0.15 | 37.50% |
| 2024-05-07 | 2024-03 | -0.4 | N/A | N/A | N/A |
| 2024-03-05 | 2023-12 | -0.4 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-09-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-03-07 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-02-10 | HC Wainwright & Co. | Upgrade | Buy | |
| 2022-07-13 | Ladenburg Thalmann | Upgrade | Buy |
Profile
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-14 | BENTSUR RON | Chief Executive Officer | 3.27M | Purchase |
| 2024-11-06 | CARSON MICHAEL J. | Officer | 87.92K | Sale |
| 2024-06-12 | HOBERMAN KENNETH | Director | 103.14K | Stock Award(Grant) |
| 2024-06-12 | KAPLAN MATTHEW L. | Director | 83.76K | Stock Award(Grant) |
| 2024-12-12 | MOSSERI MARLIO CHARLES | Beneficial Owner of more than 10% of a Class of Security | 2.61M | Purchase |
| 2024-06-12 | OLIVIERO JAMES F III | Director | 57.83K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 301.14K | 1.38M | 1.56% |
| 2024-09-29 | Baldwin Wealth Partners LLC/MA | 174.13K | 797.52K | 0.90% |
| 2024-09-29 | Geode Capital Management, LLC | 79.72K | 365.10K | 0.41% |
| 2024-09-29 | Millennium Management Llc | 68.50K | 313.73K | 0.35% |
| 2024-09-29 | Iridian Asset Management LLC | 55.38K | 253.64K | 0.29% |
| 2024-09-29 | Gsa Capital Partners Llp | 50.13K | 229.59K | 0.26% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 231.04K | 1.06M | 1.20% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 57.03K | 261.20K | 0.30% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 37.45K | 171.51K | 0.19% |
| 2024-10-30 | iShares Micro Cap ETF | 21.22K | 97.18K | 0.11% |
| 2024-10-30 | Fidelity Total Market Index Fund | 13.31K | 60.96K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.94K | 40.94K | 0.05% |